Cyclosporine Injection (IV)

Phase 3

Cyclosporine Injection (IV) is one of 6 therapeutic programs targeting Ulcerative Colitis Acute. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Ulcerative Colitis AcuteRecruiting

Ulcerative Colitis AcutePhase 3

Recruiting

Competition

Competitive Landscape

7 competitors in Ulcerative Colitis Acute

#DrugCompanyPhaseTrials

Rinvoq

AbbVie

Approved

1 2

Medrol

Pfizer

Approved

1 3

Neoral

Novartis

Approved

1 4

Rayos

RRoxane Laboratories

Approved

1 5

Cyclosporine Injection (IV)

BBerinstein, Jeffrey

Phase 3

1 6

Intravenous Methylprednisolone

IIstanbul Medeniyet University

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

ApprovedRecruiting

Ulcerative Colitis Acute

NCT05867329

Clinical

Trials by Indication[1]

Ulcerative Colitis Acute1 trial

A Sequential Multiple Assignment Randomized Trial (SMART) Feasibility Pilot Developing and Optimizing Patient-Tailored Adaptive Treatment Strategies (ATS) for Acute Severe Ulcerative Colitis (ASUC)

Recruiting·BBerinstein, Jeffrey·Approved·NCT05867329·700 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Cyclosporine Injection (IV). U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Cyclosporine Injection (IV). EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Berinstein, Jeffrey company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: BBerinstein, Jeffrey

Cyclosporine Injection (IV)

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Ulcerative Colitis Acute1 trial

References

Drug Info

Quick Facts

Related News